Advertisement

Stem Cell Transplants in Acute Myeloid Leukaemia (AML)

  • A. H. Goldstone
  • A. R. Perry
  • L. G. Robinson
  • K. Wheatley
  • A. K. Burnett
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

The 10th United Kingdom Medical Research Council (MRC) AML trial showed a reduced overall relapse rate compared to previous trials, attributed largely to increased treatment intensity. Autologous bone marrow transplantation (ABMT) was also associated with a reduced rate of relapse. These benefits, however, were partly offset by slow neutrophil and platelet recovery after later courses of chemotherapy, and in the context of ABMT, the resulting high procedural mortality (12%) from infection and/or haemorrhage led to no overall survival benefit for ABMT. The 12th MRC AML trial aims to assess the benefit of further treatment intensification through randomisation to 4 or 5 chemotherapy courses for standard risk patients, and to examine further the role of ABMT. In an attempt to overcome some of the previous problems associated with delayed haemopoietic recovery, the trial incorporates the option to collect peripheral blood stem cells (PBSCs) and administer them as additional support after course 4, 5, or in association with ABMT, with the aim of facilitating more rapid haemopoietic reconstitution. Factors associated with optimal PBSC collections will be analysed as the trial proceeds. The theoretical risk of tumour contamination of PBSC samples will be assessed, where possible, by molecular techniques, and at close of trial in terms of relative relapse rate.

Keywords

Acute Myeloid Leukae Peripheral Blood Stem Cell Peripheral Blood Stem Cell Transplantation Medical Research Council Working Party Standard Risk Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burnett AK, Goldstone AH, Milligan DW, Prentice AG (Co-ordinators) (1994) Medical Council Working Party on leukaemia in adults, Acute Myeloid Leukaemia Trial-12Google Scholar
  2. 2.
    Burnett AK, Goldstone AH, Stevens R, Hann I, Rees JK, Wheatley K for the UK MRC Leukaemia Working Parties (1995) Biochemical characteristics of disease determine the outcome of allogeneic or autologous BMT in AML CR1. Blood 86(10) Si: ASH abstract no. 2452Google Scholar
  3. 3.
    Wheatley K, Burnett AK, Goldstone AH, Hann I, Stevens R, Rees JK, Gray R (1995) A simple robust and highly predictive prognostic index for the determination of risk directed therapy in acut myeloid leukaemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML 10 trialGoogle Scholar
  4. 4.
    Yin JAL, Rees JAH (Co-ordinators) ( 1992, amended 1995 ) Medical Research Council Working Party on leukaemia in adults, Relapsed Acute Myeloid Leukaemia TrialGoogle Scholar
  5. 5.
    Zittoun RA, Mandelli F, Willemze R, de Witte T et al. for the European Organisation for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) leukaemia cooperative groups (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. NEJM 332(4): 217–223PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • A. H. Goldstone
    • 1
  • A. R. Perry
    • 1
  • L. G. Robinson
    • 2
  • K. Wheatley
    • 3
  • A. K. Burnett
    • 2
  1. 1.University College London HospitalsUK
  2. 2.University of Wales College of MedicineCardiffUK
  3. 3.Radcliffe InfirmaryClinical Trial Service Unit.UK

Personalised recommendations